127 related articles for article (PubMed ID: 11844900)
1. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
Hwang WJ; Yao WJ; Wey SP; Shen LH; Ting G
Eur Neurol; 2002; 47(2):113-7. PubMed ID: 11844900
[TBL] [Abstract][Full Text] [Related]
2. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
3. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
[TBL] [Abstract][Full Text] [Related]
4. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
5. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
[TBL] [Abstract][Full Text] [Related]
6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
7. Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia: an [123I]iodobenzamide single photon emission computed tomography study.
Schröder J; Bubeck B; Silvestri S; Demisch S; Sauer H
Psychiatry Res; 1997 Sep; 75(2):115-23. PubMed ID: 9351493
[TBL] [Abstract][Full Text] [Related]
8. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls.
Cordes M; Hierholzer J; Schelosky L; Poewe W; Cordes I; Horowski R; Eichstaedt H; Schmidt D; Felix R
Adv Neurol; 1993; 60():525-8. PubMed ID: 8420183
[No Abstract] [Full Text] [Related]
9. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
[TBL] [Abstract][Full Text] [Related]
10. [
Stark AJ; Smith CT; Petersen KJ; Trujillo P; van Wouwe NC; Donahue MJ; Kessler RM; Deutch AY; Zald DH; Claassen DO
Neuroimage Clin; 2018; 18():433-442. PubMed ID: 29541577
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
Pizzolato G; Chierichetti F; Rossato A; Briani C; Dam M; Borsato N; Saitta B; Zanco P; Ferlin G; Battistin L
Eur Neurol; 1993; 33(2):143-8. PubMed ID: 8467821
[TBL] [Abstract][Full Text] [Related]
12. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
[No Abstract] [Full Text] [Related]
13. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Tedroff J; Aquilonius SM; Hartvig P; Bredberg E; Bjurling P; Långström B
Acta Neurol Scand; 1992 Feb; 85(2):95-102. PubMed ID: 1574995
[TBL] [Abstract][Full Text] [Related]
14. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
[No Abstract] [Full Text] [Related]
15. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
16. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
[TBL] [Abstract][Full Text] [Related]
17. Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia.
Yang YK; Yeh TL; Chiu NT; Lee IH; Chen PS; Lee LC; Jeffries KJ
Psychiatry Res; 2004 Sep; 131(3):209-16. PubMed ID: 15465290
[TBL] [Abstract][Full Text] [Related]
18. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH
Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
[TBL] [Abstract][Full Text] [Related]
19. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
20. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
Tibbo P; Silverstone PH; McEwan AJ; Scott J; Joshua A; Golberg K
J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
